CA9 and breast carcinoma: Whereas CA9 and CA12 are prognostic markers and proposed pharmacological targets in breast cancer [18, 19], the consequences of these and other carbonic anhydrases in specific breast cancer molecular subtypes remain unclear [6, 20].